OR WAIT null SECS
October 11, 2023
Under this agreement, Acuitas Therapeutics’ LNP technology platform will be transferred to BIOVECTRA for use in manufacturing mRNA-based therapies.
September 28, 2023
With the two new GMP-grade mRNA manufacturing sites in Germany, MilliporeSigma can now offer fully integrated mRNA services.
July 14, 2023
German manufacturer metabion is conducting a multi-million euro expansion of its oligonucleotide manufacturing capacity in Munich East.
July 07, 2023
Camena Bioscience has completed $10 million in Series A financing on the back of growing demand for DNA synthesis.
May 16, 2023
Synthego has opened its new GMP-compliant RNA manufacturing facility in Redwood City, Calif., for CRISPR-enabled genomics therapeutics.
May 15, 2023
To prepare for emerging mRNA technologies, it is necessary to adapt fill/finish and cold chain capabilities.
May 10, 2023
The market potential of nucleic acid-based therapies have been pushed into the spotlight following the success of the COVID-19 vaccines.
April 02, 2023
The COVID-19 vaccines opened the door to powerful market potential for other nucleic acid-based therapies.
March 01, 2023
Considerable efforts have been made over the years to resolve the key issues of stability and delivery of RNA-based therapeutics.
February 22, 2023
Agilent’s therapeutic nucleic acids facility gains architectural design support from CRB.